@article{WAN2025114196,
title = {Cu0-based nanoparticles boost anti-tumor efficacy via synergy of cuproptosis and ferroptosis enhanced by cuproptosis-induced glutathione synthesis disorder},
journal = {Colloids and Surfaces B: Biointerfaces},
volume = {245},
pages = {114196},
year = {2025},
issn = {0927-7765},
doi = {https://doi.org/10.1016/j.colsurfb.2024.114196},
url = {https://www.sciencedirect.com/science/article/pii/S0927776524004557},
author = {Yichen Wan and Junge Chen and Jiaxuan Li and Zelong Chen and Yi Wang and Jiahui Li and Zhichao Pei and Yuxin Pei},
keywords = {Cuproptosis, Ferroptosis, Glutathione synthesis, Zero-valent copper, Synergistic therapy},
abstract = {Apoptotic resistance of tumor often leads to poor efficacy from mono-therapy based on apoptosis. Cuproptosis, a new type of non-apoptotic cell death related to mitochondrial dysfunction, can alter metabolism and enhance ferroptosis, providing a promising strategy for effective synergistic cancer treatment. In this work, Cu0-based nanoparticles (denoted as HA-ZCu) were successfully developed to improve anti-tumor efficacy by combining cuproptosis with enhanced ferroptosis, which was achieved by cuproptosis-induced glutathione synthesis disorder. In vitro studies revealed that HA-ZCu effectively induced cuproptosis and ferroptosis in HepG2 cells. Moreover, HA-ZCu induced mitochondrial dysfunction and decreased intracellular adenosine triphosphate (ATP), glutamate, and glutathione, demonstrating the effective synergy. In vivo studies further approved the synergistic therapeutic efficacy of HA-ZCu, where the inhibition rate of tumor growth reached 83.2â€¯%. This work represents the first example of enhanced anti-tumor efficacy via cuproptosis and ferroptosis synergy through cuproptosis-induced glutathione synthesis disorder.}
}